IMIDAZOQUINOLEINE DERIVATIVES

专利摘要:
This invention relates, inter alia, to novel imidazoquinoline derivatives and their use in therapy, particularly as vaccine adjuvants.
公开号:BE1024865B1
申请号:E2017/5621
申请日:2017-09-05
公开日:2018-07-31
发明作者:Helene G. Bazin-Lee；David Burkhart；Michael Cochran；Jay T. Evans；David A. Johnson
申请人:Glaxosmithkline Biologicals Sa；
IPC主号:

专利说明:

(73) Holder (s):
GLAXOSMITHKLINE BIOLOGICALS SA
1330, RIXENSART
Belgium (72) Inventor (s):
BAZIN-LEE Helene G. 59840-3607 HAMILTON United States
BURKHART David 59840-3607 HAMILTON United States
COCHRAN Michael 59840-3607 HAMILTON United States
EVANS JayT. 59840-3607 HAMILTON United States
JOHNSON David A. 59840-3607 HAMILTON United States (54) IMIDAZOQUINOLEINE DERIVATIVES (57) The invention relates inter alia to new imidazoquinoline derivatives and their use in therapy, particularly as vaccine adjuvants.
fc comparative example 2 <· Comparative example 3 A Example 1 H 'Comparative free 1
MITE
FIG 1
BELGIAN INVENTION PATENT
FPS Economy, SMEs, Classes
Medium & Energy
Intellectual Property Office
Publication number: 1024865
Deposit number: BE2017 / 5621
International Classification: C07D 487/14 A61K 31/4745 C07F
9 / 6561A61P 37/04
Issue date: 07/31/2018
The Minister of the Economy,
Having regard to the Paris Convention of March 20, 1883 for the Protection of Industrial Property;
Considering the law of March 28, 1984 on patents for invention, article 22, for patent applications introduced before September 22, 2014;
Given Title 1 “Patents for invention” of Book XI of the Code of Economic Law, article XI.24, for patent applications introduced from September 22, 2014;
Having regard to the Royal Decree of 2 December 1986 relating to the request, the issue and the maintenance in force of invention patents, article 28;
Given the patent application received by the Intellectual Property Office on 05/09/2017.
Whereas for patent applications falling within the scope of Title 1, Book XI of the Code of Economic Law (hereinafter CDE), in accordance with article XI. 19, §4, paragraph 2, of the CDE, if the patent application has been the subject of a search report mentioning a lack of unity of invention within the meaning of the §ler of article XI.19 cited above and in the event that the applicant does not limit or file a divisional application in accordance with the results of the search report, the granted patent will be limited to the claims for which the search report has been drawn up.
Stopped :
First article. - It is issued to
GLAXOSMITHKLINE BIOLOGICALS SA, Rue de l'Institut 89, 1330 RIXENSART Belgium;
represented by
PRONOVEM - Office Van Malderen, Avenue Josse Goffin 158, 1082, BRUXELLES;
a Belgian invention patent with a duration of 20 years, subject to payment of the annual fees referred to in article XI.48, §1 of the Code of Economic Law, for: DERIVES D'IMIDAZOQUINOLEINE.
INVENTOR (S):
BAZIN-LEE Helene G „c / o GlaxoSmithKline, 553 Old Corvallis Road, 59840-3607, HAMILTON;
BURKHART David, c / o GlaxoSmithKline, 553 Old Corvallis Road, 59840-3607, HAMILTON;
COCHRAN Michael, c / o GlaxoSmithKline, 553 Old Corvallis Road, 59840-3607, HAMILTON;
EVANS Jay T., c / o GlaxoSmithKline, 553 Old Corvallis Road, 59840-3607, HAMILTON;
JOHNSON David A., c / o GlaxoSmithKline, 553 Old Corvallis Road, 59840-3607, HAMILTON;
PRIORITY (S):
09/07/2016 US 62384618;
DIVISION:
divided from the basic application: filing date of the basic application:
Article 2. - This patent is granted without prior examination of the patentability of the invention, without guarantee of the merit of the invention or of the accuracy of the description thereof and at the risk and peril of the applicant (s) ( s).
Brussels, 07/31/2018, By special delegation:
BE2017 / 5621
IMIDAZOQUINOLEIN DERIVATIVES
Field of 1 ¹ invention
The present invention relates to new imidazoquinoline derivatives, methods for their preparation, compositions containing them, and their use in therapy especially as vaccine adjuvants.
Context of the invention
The improvement and simplification of microbial vaccines and the use of synthetic and recombinant subunit antigens to improve manufacturability and safety have resulted in a decrease in the potency of vaccines. This has led to studies on the coadministration of adjuvants with antigens to potentiate the activity of vaccines and the weak immunogenicity of synthetic and recombinant epitopes. Adjuvants are additives that enhance humoral and / or cell-mediated immune responses to a vaccine antigen. However, the design of vaccine adjuvants has historically been difficult due to the complex nature of the molecular mechanisms involved in the function of the system.
BE2017 / 5621 immune. Although the addition of microbial components has long been known to enhance adaptive immune responses, it is only recently that it has been shown that Toll-like receptors (TLR) on cells involved in immune surveillance, such as that epithelial and dendritic cells, involve a large number of these microbial products via the so-called "pathogenic molecular motifs" or PAMP. Many vaccine adjuvants and independent immunomodulators appear to interact with members of the LRT family.
Of the 10 known TLRs that have been identified in humans, five are associated with the recognition of bacterial components (TLR 1, 2, 4, 5, 6) and four others (TLR 3, 7, 8, 9) appear to be restricted to cytoplasmic compartments and are involved in the detection of viral RNA (TLR 3, 7, 8) and unmethylated DNA (TLR9) (Iwasaki, A., Nat Immunol 2004, 5, 987). Activation of TLR regulates intracellular signaling pathways and leads to gene expression through interaction with intracellular adapter molecules such as MyD88, TRIF, TIRAP, and TRAM (Akira, S. Nat Rev Immunol 2004, 4, 499; Takeda, K. Semin Immunol 2004, 16, 3). These adapter molecules can differentially regulate the expression of inflammatory cytokines / chemokines and type I interferons (IFNa / ß), which can lead to preferential amplification of humoral and cell-mediated immune responses specific for the antigen. (Zughaier, S. Infect Immun 2005, 73, 2940).
BE2017 / 5621
Humoral immunity is the main line of defense against bacterial pathogens, while induction of cytotoxic T lymphocytes (CTLs) appears to be crucial for protective immunity in viral disease and cancer.
In the case of the activation of TLR7 and TLR8, a few different classes of small molecule mimetics of natural sRNAs (rich in U and / or G) ligands have been identified. These include certain antiviral compounds related to metabolites of oxidized guanosines (oxoguanosines), which mainly interact with TLR7 (Heil, F. Eur J Immunol 2003, 33, 2987; Hemmi, 2002) and adenine derivatives which involve TLR7 and / or TLR8. The immunostimulation capacity of these compounds has been attributed to TLR / MyD88-dependent signaling pathways and to the production of cytokines, including IL-6 and type I interferons (particularly interferon a) and II. Activation of TLR7 or TLR8 leads to upregulation of costimulatory molecules (e.g. CD-40, CD-80, CD-86) and molecules of
MHC class I and II on dendritic cells (DC). DC are the main cells of the immune system involved in the capture and presentation of antigens to T lymphocytes. Plasmacytoid dendritic cells (pDC), preferentially express TLR7, are professional cells producing interferon a; while mDCs only express TLR8. Activation of TLR8 on mDCs leads to preferential production of proinflammatory cytokines such as
The who
BE2017 / 5621
IL-12, TNF-α, and IFN-γ and cell-mediated immunity (BMI). TLR7 agonists have been shown to be more efficient in the production of IFN-a and IFN-regulated cytokines, while TLR8 agonists, which lead to the reversal of the function of CD4 + regulatory cells ( Treg), are more effective in inducing proinflammatory cytokines such as TNF-α and IL-12, suggesting that activation of TLR7 may be more important for antibody responses (Th2-like responses) while activation of TLR8 will induce BMI or Thl-type immune responses (Gordon J Immunol 2005, 1259).
A class of adenine derivatives active on TLRs which has attracted keen attention consists of 1Himidazo [4,5-c] quinolines. The prototype member of this class, imiquimod, has been found to be effective against genital papillomavirus infections, actinic keratosis and basal cell carcinoma when applied topically as a cream. Imiquimod, however, has relatively low interferon-inducing activity in both oral and topical preparations and both oral and topical preparations are not without side effects. In fact, serious side effects have been reported in an HCV clinical trial with imiquimod. Significant immunological "fingerprint" of TLR7 agonists in general has led to concerns about toxicity: clinical trials with another TLR7 agonist ANA-975, an oxoguanosine derivative, have been suspended due to toxicity concerns .
BE2017 / 5621
Another member of the 1H-imidazo [4,5-c] quinolone class of TLR7 / 8 ligands is resiquimod. Resiquimod also activates TLR7 in macrophages and DC in a manner dependent on MyD88 either directly or indirectly via an accessory molecule and positively regulates costimulatory molecules and MHC-I / II in DC. Unlike imiquimod, the more potent and toxic resiquimod is also a ligand for TLR8 signaling, which leads to the reversal of the function of CD4 + regulatory cells (Treg).
Lipid conjugates of nucleoside drugs are known in the art to enhance oral bioavailability in general as well as to allow incorporation of the resulting "nucleolipid" into the lipid membranes of liposomes (Rosemeyer, H. Chemistry & Biodiversity 2005, 2, 977 -1063). The incorporation of sensitive and / or highly active molecules into liposomes establishes a slow release support system or a molecular deposit which protects the molecule against degradation and reduces toxic side effects. However, it has often been discovered that lipid conjugates are less biologically active than the parent molecule.
Certain lipid imidazoquinoline derivatives have been described in US Pat. No. 8,624,029 (Johnson) and these compounds have advantages over the corresponding non-lipid analogs.
It remains an objective to discover other effective and safe vaccine adjuvants.
BE2017 / 5621
Brief description of 1 ¹ invention
Here we describe new lipid imidazoquinoline derivatives. The compounds of the invention have been shown to be inducers of cytokines such as IFN-a, IFN-γ and TNF-a and are agonists of TLR7 and / or TLR8. These compounds are expected to be useful as vaccine adjuvants in the therapeutic or prophylactic treatment of infectious diseases and cancer among others.
Brief description of the figures
FIG. 1 represents a plot of curves of various compounds tested in the reporter test for hTLR7 agonists in HEK293 cells.
FIG. 2 represents a plot of curves of various compounds tested in the reporter test for hTLR8 agonists in HEK293 cells.
FIG. 3 represents a plot of curves of various compounds tested in the reporter test for hTLR7 agonists in HEK293 cells.
FIG. 4 represents a plot of curves of various compounds tested in the reporter test for hTLR8 agonists in HEK293 cells.
FIG. 5 represents a plot of curves of various compounds tested in the reporter test for hTLR7 agonists in HEK293 cells.
FIG. 6 represents a plot of curves of various compounds tested in the reporter test for hTLR8 agonists in HEK293 cells.
BE2017 / 5621
FIG. 7 represents a plot of curves of various compounds tested in the reporter test for hTLR7 agonists in HEK293 cells.
FIG. 8 represents a plot of curves of various compounds tested in the reporter test for hTLR8 agonists in HEK293 cells.
Figure 9 shows a plot of curves of various
compounds tested in the d test . 'indi jction of IFN-γ in hPBMC. Figure 10 shows a plotting curves various compounds tested in the test IFN induction a in hPBMC. Figure 11 shows a plotting curves various compounds tested in the test IFN induction γ in hPBMC. Figure 12 shows a plotting curves various compounds tested in the test IFN induction a in hPBMC. Figure 13 shows a plotting curves
various compounds tested in the induction test of TNF-a in hPBMC.
FIG. 14 represents a plot of curves of various compounds tested in the IFNα induction test in hPBMC.
FIG. 15 represents a plot of curves of various compounds tested in the test of induction of TNF-a in hPBMC.
Figure 16 shows a plot of curves of various compounds tested in the induction test for IFN-a in hPBMC.
BE2017 / 5621
FIG. 17 represents a plot of curves of various compounds tested in the test for induction of TNF-a in hPBMC.
Figure 18 shows a schematic representation of salting processes, as described here.
Detailed description of the invention
Throughout this application, references are made to various embodiments relating to compounds, compositions, and methods. The various embodiments described are intended to provide various illustrative examples and should not be construed as descriptions of variant species. Rather, it should be noted that the descriptions of the various embodiments provided here may overlap in their scope. The embodiments discussed here are merely illustrative and are not intended to limit the scope of the present invention.
It should be understood that the terminology used here is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention. In this specification and in the claims which follow, reference will be made to a number of terms which will be defined as having the following definitions.
"Alkyl" refers to monovalent saturated aliphatic hydrocarbyl groups having, according to various embodiments, up to 24 carbon atoms and, in certain embodiments, from 1 to 6 carbon atoms and, in other embodiments production of 2 to 6 carbon atoms. "Alkyl (C _x to C _y )" refers
BE2017 / 5621 to alkyl groups having from x to y carbon atoms. This term includes, for example, linear and branched hydrocarbyl groups such as methyl (CH3-), ethyl (CH3CH2-), n-propyl n-butyl sec-butyl n-pentyl (CH3CH2CH2-), isopropyl groups. ((CH ₃ ) 2CH-), (CH3CH2CH2CH2-), isobutyl ((CH ₃ ) 2CHCH2-), ((CH ₃ ) (CH3CH2) CH-), t-butyl ((CH ₃ ) ₃ C-), ( CH3CH2CH2CH2CH2-), and neopentyl ((CH ₃ ) 3CCH2-).
"Alkylene" means a bivalent saturated aliphatic hydrocarbyl group having, according to various embodiments, from 2 to 6 carbon atoms. This term includes, for example, linear and branched hydrocarbyl groups such as ethylene (-CH2CH2-), n-propylene (-CH2CH2CH2-), isopropylene (-CH (CH3) CH-), n-butylene groups (-CH2CH2CH2CH2-), isobutylene (-CH (CH ₃ ) CHCH ₂ -), sec-butylene (CH (CH3CH2) CH-) and n-pentylene (-CH2CH2CH2CH2CH2CH2-).
"Alkoxy" refers to the group -O-alkyl in which alkyl is defined herein. Alcoxy includes, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, sec-butoxy, and n-pentoxy groups.
"Amino" refers to the group -NHR ⁶ where R ⁶ is independently selected from a hydrogen atom, C1 to C6 alkyl and C2 to C6 alkenyl, and generally represents H or Me. However, the expression alkyl C1-C6-amino means (C1-C6 alkyl) HN-, C3-C6 cycloalkyl-C1-C6 alkyl-amino means (C3-C6 cycloalkyl) (C1-Cs alkyl) N- and the expression C1-C6 alkoxy-C1-C6 alkyl-amino means (C1-C6 alkoxy) (C1-C6 alkyl) N-.
BE2017 / 5621 "Cycloalkyle" refers to a saturated carbocyclic group of 3 to 14 carbon atoms (for example, 3 to 8 carbon atoms, particularly 3 to 6 carbon atoms) and no ring heteroatoms.
"Cycloalkenyl" refers to an unsaturated carbocyclic group of 5 to 14 carbon atoms (for example, 6 to 8 carbon atoms, such as 6 or 7 carbon atoms) and no ring heteroatom and containing at least one carbon double bond - cycle carbon.
"Alkenyl" refers to an unsaturated alkyl group which contains at least one carbon-carbon double bond. For example, it can contain one, two or three double bonds but more generally it will contain 2 or most usually a double bond
Unless otherwise indicated, the nomenclature of substituents which are not explicitly defined here is deduced by naming the terminal part of the functionality followed by the adjacent functionality towards the fixing point. For example, the substituent "C3 to C6 cycloalkyl-C1 to C6 alkoxy" refers to the group (C3 to C6 cycloalkyl) (C1 to C6 alkoxy) -. It should be understood that the above definitions are not intended to include unacceptable substitution profiles (for example, methyl substituted by 5 fluoro groups). Such inadmissible substitution profiles are well known to those skilled in the art.
The compounds of the subject invention are generally described by formula (I):
BE2017 / 5621
wherein :
Ri represents -O-Z- (P (= 0) -OH) -O-Y-A
R2 represents H, C1-C6 alkyl, C1-C6 alkyl-amino, C1-C6 alkoxy, C3-C6 cycloalkyl-C1-C6 alkyl, C3-C6 cycloalkyl-C1-C6 alkyl amino, C3-C6 cycloalkyl-C1-C6 alkoxy, C1-C6 alkoxy-C1-C6 alkyl, C1-C6 alkoxy-C1-C6 alkyl-amino, C1-C6 alkoxy-C1-alkoxy C6; and optionally substituted at the end with a hydroxyl, amino, -NHNH2, N3, -C ^ CH, -COOH, or maleimido group;
Z represents a group (C2 to C6-0 alkylene) _q ;
Y represents a group (C2 to C6-0 alkylene) _r ;
q represents an integer 1 to 6;
r represents 0 or an integer 1 to 20;
R3 is C2-C6-OH alkylene, C2-C6-NH2 alkylene, C2-C5-CH2-OH alkenyl or C2-C5-CH2-NH2 alkenyl;
Y î
X ·. ^ 'V
Xi
A represents in which:
R4 represents H, C4 to C24 alkyl, C4 to C24 alkenyl, —CO-C3 to C23 alkyl, or —CO C3 to C23 alkenyl;
BE2017 / 5621
Rs represents a C4 to C24 alkyl group, C4 to C24 alkenyl, —CO-C3 to C23 alkyl, or — C3 to C24 alkenyl represents 0 or an integer 1 to 6; or one of their pharmaceutically acceptable salts.
Suitably, R2 represents H, a C1-C1 alkyl or C1-dalkoxy C1-C1alkyl group, especially H, a C1-C1alkyl group or C1-C1alkoxy-C1-C3alkyl . For example, R2 represents H, an n-butyl group or -CH2OCH2CH3 especially n-butyl.
Suitably, q represents an integer 1 to 3, particularly 1 or 3 and especially 1.
Suitably, r represents 0 or an integer 1 to 6, for example, 0 or an integer 1 to 3, such as 0 or 3 especially 0.
Suitably, R3 represents a C2 to d-OH alkylene or a d to d-NER alkylene group, particularly d to d-OH alkylene and especially CH2CH2OH.
Suitably, p represents an integer 1 to 3.
Suitably, A represents'
In a preferred embodiment, the subject compounds of the invention are generally described by the formula (IA):
BE2017 / 5621
wherein :
Ri represents -O-Z- (P (= 0) -OH) -O-Y-A
R2 represents H, C1-CA alkyl or C1-C3 alkoxy-C1-C3 alkyl;
Z represents a group (C2 to C6-0 alkylene) _q ;
Y represents a group (C2 to C6-0 alkylene) _r ;
q represents an integer 1 to 6;
r represents 0 or an integer 1 to 20;
R3 represents a C2 to CA-OH alkylene group;
A represents iiiiiiiiiiiiiyii in which:
R4 represents H, a group —CO-C 1 -C 23 alkyl, or —CO-alkenyl C 1 -C 23;
R5 represents a group —CO-C3 to C23 alkyl, or - C3 to C23 alkenyl;
or one of their pharmaceutically acceptable salts.
Suitably, R2 represents H, a nbutyl group or CH3CH2OCH2- especially n-butyl.
Suitably, Z represents ((CH2) 2O) _q especially CH2CH2O or Z represents CH2CH2CH2CH2O, especially CH2CH2O.
BE2017 / 5621
Suitably, Y represents ((CH2) 2O) _r .
Suitably, q represents an integer 1 to 3, particularly 1 or 3 and especially 1.
Suitably, r represents 0 or an integer 1 to 6, for example, 0 or an integer 1 to 3, such as 0 or 3 especially 0.
Suitably, R3 represents -CH2CH2OH.
In one embodiment, R4 represents H and R5 represents a group —CO-C3 to C23 alkyl, or-C3 to C23 alkenyl. In an alternative embodiment, R4 and R5 independently represent a group —CO-C3 to C23 alkyl, or-C3 to C23 alkenyl.
Suitably, R4 and Rs independently represent a lauroyl, myristoyl, palmitoyl, oleoyl or linoleoyl group, preferably oleoyl or palmitoyl, especially oleoyl. Suitably, R4 and Rs are identical.
The compounds of the subject invention can be prepared by reaction of a compound of formula (II):


wherein :
Ria represents -O-Z-H;
and Z, R2 and R3 are defined as for the compounds of formula (I);
BE2017 / 5621 or one of their protected derivatives; with a compound of formula (III)
Pg-OP (N-iPr ₂ ) -OYA (III) in which A is defined as for the compounds of formula (I) and P _g represents a protective group, generally CNCH2CH2-, followed by the oxidation of P (III) to P (V) and the removal of protecting groups.
Suitable conditions for carrying out this reaction include combining the components in the presence of imidazolium triflate (Imid-OTf) in an inert organic solvent such as CH2Cl2. The reaction product can be purified or oxidized directly, followed by removal of the protecting groups.
Suitably, the hydroxyl group of R3 is protected by an acyl group, such as a levulinoyl group. Deprotection can be achieved by treatment with hydrazine.
When R4 represents a hydrogen atom, it can be protected in the form of an ether, for example, with tetrahydropyran (THP). This group can be removed at the desired stage by treatment with an acid (eg, HCl).
The compounds of formula (II) or one of their protected derivatives can be prepared by reaction of a compound of formula (IV)
BE2017 / 5621
in which :
R.2 and R3 are defined as for the compounds of formula (I);
or one of their protected derivatives; with a compound of formula (V)
Li-ZH (V) in which Z is as defined as for the compounds of formula (I) and Li represents a releasable group or one of its protected derivatives.
Examples of Li releasable groups include a halogen atom such as Br, mesylate, tosylate groups and the like, especially Br.
Generally, the compound of formula (V) will be used in a form in which the terminal hydroxyl group of group Z is protected. Suitable hydroxy protecting groups include acyl groups such as an acetyl group or in the form of silyl ethers such as t-butyldimethyl silyl ether (TBS), or in the form of an ether such as benzyl ether (Bn).
The conditions for the reaction of the compounds of formulas (IV) and (V) include the combination of the reactants in the presence of cesium carbonate in a
BE2017 / 5621 organic solvent such as DMF followed by aqueous treatment and purification.
Alternatively, the compounds of formula (II) or their protected derivatives can be prepared by heating a compound of formula (VI)
in which :
Ria represents -O-Z-H;
and Z, R2 and R3 are defined as for the compounds of formula (I) or one of their derivatives protected with an oxidizing agent such as CH2CO3H or 3-chloroperoxybenzoic acid in an inert solvent such as ethanol or methylene chloride to form an N-oxide, this followed by a reaction to form an activated ester, for example, with pTsCl or methanesulfonyl chloride in an inert solvent such as methylene chloride, this followed by amination with ammonia or an ammonia derivative such as NH4OH in an inert solvent such as methylene chloride. The reaction also proceeds if the N-oxide is treated with ammonia or an ammonia derivative before pTsCl or methanesulfonyl chloride (or another reagent to form an activated ester).
Suitably, the hydroxyl group of R3 is protected by an acyl group, such as a levulinoyl group.
BE2017 / 5621
Deprotection can be achieved by treatment with hydrazine. Other details of this conversion can be gleaned by reference to document WO 05/020999 (the content of which is incorporated herein by reference in its entirety) and in particular the reaction scheme 1 where similar treatments are described.
The compounds of formula (VI) or one of their protected derivatives can be prepared by reaction of a compound of formula (VII)
in which :
R.2 and R3 are defined as for the compounds of formula (I);
or one of their protected derivatives; with a compound of formula (V)
Ll-ZH (V)
in which Z East such as defined as for compounds of formula (I) and Li represented a group releasable or one of his derivatives protected. Generally, the compound of formula (V) will
used in a form in which the terminal hydroxyl group of group Z is protected. Hydroxy groups19
BE2017 / 5621 suitable protectors include esters formed from acyl groups, such as acetyl or in the form of silyl ethers such as tbutyldimethylsilyl ether (TBS) or in the form of an ether such as ether benzyl (Bn).
A suitable releasable group Li is a halogen atom such as Br, mesylate, tosylate groups and the like, especially Br.
The examples of conditions for this reaction are the same as those for the reaction of the compounds of formulas (IV) and (V).
Suitably, the hydroxyl group of R3 is protected by an acyl group, such as a levulinoyl group. Deprotection can be achieved by treatment with
Hydrazine.
Suitably, the phenolic hydroxyl group is protected in the form of an ether group, for example, in the form of benzyl ether. Deprotection can be obtained by reduction, for example, with H2 gas on Pd / C.
The synthesis of the compounds of formula (IV) and (VII) and their protected derivatives is illustrated in diagram 1 below:
BE2017 / 5621
Diagram 1
Suitably, L2 represents a halogen atom, especially Cl.
Other details of the conversions shown in scheme 1 can be gleaned with reference to document WO 05/020999 (the content of which is incorporated herein by reference in its entirety) and in particular reaction scheme 1 where similar processes are described.
The compounds of formula (III) or one of their protected derivatives can be prepared by reaction of a compound of formula (VIII)
H-O-Y-A (VIII) with a compound of formula (IX)
P _g OP (N-iPr ₂ ) 2 (IX) and Pg represents a protective group, generally CNCH2CH2-.
BE2017 / 5621
The conditions for the reaction of the compounds of formula (VIII) and (IX) include the combination of the reagents in an inert solvent such as CH2Cl2 in the presence of tetrazole or another coupling reagent known in the art.
The intermediate compounds of formula (II) and (VI) are new and are claimed as an aspect of the invention. As noted in the examples, the compounds of formulas (II) and (IV) may have at least some of the biological activity of the compounds of formula (I).
Thus, the invention provides a compound of formula (II):
in which :
Ria represents -O-Z-H;
and Z, R2 and R3 are defined as for the compounds of formula (I) and (IA);
or one of its protected derivatives.
The invention also provides a compound of formula (VI)
BE2017 / 5621
in which :
Ria represents -O-Z-H;
and Z, R2 and R3 are defined as for the compounds of formula (I) and (IA);
or one of its protected derivatives.
In the compounds of formula (II), (IV), (VI) and (VII), the alcohol groups can be protected in the form of an ester, for example, by reaction with an acyl group (for example, acetyl or levulinoyl) or they can be protected in the form of an ether, for example, in the form of an ether formed with THP or a benzyl group. In the compounds of formula (II), (IV), (VI) and (VII), the amine groups can be protected in the form of an amide, for example, by reaction with an acyl group (for example, acetyl or levulinoyl).
The compounds of formula (V), (VIII) and (IX) are known or can be prepared by known methods.
The starting compounds and the other reagents shown in Scheme 1 are known or can be prepared by known methods.
The pharmaceutically acceptable salts of the compounds of the invention may include salts of acids formed with group 1 metal cations (such as sodium and potassium ions) and cations
BE2017 / 5621 of group 2 metals (such as calcium and magnesium ions) as well as with inorganic cations such as ammonium ion or other quaternary ammonium ions (such as choline) and basic salts formed with inorganic anions such as a halide (for example, chloride, bromide), phosphate, sulfate and organic anions (for example, mesylate, succinate, maleate and acetate). The preferred salts are salts formed with choline. In specific embodiments, the salt is a choline bicarbonate salt or a choline hydroxide salt.
The invention also provides methods of making pharmaceutically acceptable salts of a lipidated imidazoquinoline derivative. In one embodiment, such salting methods comprise a method for preparing a choline salt of a lipidated imidazoquinoline derivative, comprising:
(at) the dissolution of the compound in a vehicle aqueous; (b) adding the choline salt; and (vs) the mixture of the compound and the salt of choline, in which, the process does not include
the use of an organic solvent. In some embodiments, the method does not include a drying step.
In another embodiment, the salting methods of the invention comprise a method of preparing a choline salt of a lipidated imidazoquinoline derivative, comprising:
(a) dissolving the compound in an organic solvent;
BE2017 / 5621 (b) addition of the choline salt;
(c) mixing the compound and the choline salt, (d) removing the organic solvent to produce a dried salt, and (e) dissolving the dried salt in an aqueous vehicle;
wherein the method does not include a vacuum drying step. In one embodiment, the organic solvent used in the salting process is tetrahydrofuran (THF). In a further embodiment, the choline salt is selected from choline bicarbonate and choline hydroxide.
In certain embodiments, the lipidated imidazoquinoline derivative is a lipidated imidazoquinoline derivative described herein. In certain embodiments, the aqueous vehicle used in the salting processes of the invention is water, optionally containing glycerol (for example, 1%,%, 5% glycerol). In some embodiments, the choline salt is selected from choline bicarbonate and choline hydroxide.
In some embodiments, the salting methods involve mixing by sonication or mechanical breakdown. The mixing is carried out for 10 to 120 minutes; preferably 15 to 90 minutes; more preferably for at least 30 minutes. The mixing is carried out at a temperature between about 20 ° C and about 80 ° C; as between about 20, 30 or 40 ° C and about 60, 70, or 80 ° C.
The salting methods of the invention optionally include a sterilization step by filtration.
BE2017 / 5621
Sterilization by filtration can be accomplished, for example, using a 0.22 µm filter, such as a 0.22 µm syringe filter.
The subject compounds of the invention are useful as a pharmaceutical substance and particularly as vaccine adjuvants (i.e., as immunostimulants). The invention provides a pharmaceutical composition or a vaccine composition or an immunogenic composition comprising a compound of the invention. Such compositions generally include a suitable diluent or carrier, such as water. The composition can be prepared in dry form for reconstitution with water before administration. Such compositions may be based on a liposome or on another nanoparticulate composition in which the compound of the invention is dispersed or an oil-in-water composition in which the compound of the invention is dispersed. Such compositions may contain other immunostimulants including saponins such as QS21, lipopolysaccharides including MPL and 3D-MPL, CpG oligonucleotides, other TLR7 and TLR8 agonists (such as imiquimod or the resiquimod) and their combinations.
Such compositions generally contain a vaccine antigen (or more than one). Examples of antigens include pathological antigens including antigens derived from pathogens including viruses (such as HIV, HAV, HBV, HCV, HPV, influenza virus, human rhinovirus, virus syncytial), bacteria (such as
BE2017 / 5621
Corynebacterium diphtheriae, Bordetella pertussis, Clostridium tetani and toxins secreted in this way, Mycobacterium tuberculosis, Neisseria spp. , Meningococcus spp., Chlamydia spp.), And protozoa (such as Plasmodium spp.) Which cause infectious diseases and cancer antigens (such as MAGE).
In a specific embodiment, the antigen is an influenza virus antigen, for example, a fractionated influenza virus antigen such as a pandemic influenza virus antigen.
In a specific embodiment, the antigen is a polysaccharide antigen or an antigen containing a polysaccharide.
In other embodiments, the compounds of the invention can be administered orally in the form of capsules. In other embodiments, the compounds of the invention can be administered topically to a skin or mucosal surface. In such embodiments, the compounds of the invention can be combined with conventional topically acceptable diluents.
The invention provides a method of inducing an immune response in a mammal which comprises administering to a mammal in need of an immunostimulatory amount of a compound of the invention or a composition containing it (by example, a composition described above). The invention also provides a compound of the invention or a composition containing it (for example, a composition described above) for use in inducing an immune response in a mammal. The invention
BE2017 / 5621 also provides the use of a compound of the invention or a composition containing it (for example, a composition described above) in the manufacture of a medicament for the induction of an immune response in a mammal.
The induced immune response may include the induction of a type 1 interferon response and / or the induction of proinflammatory cytokines such as IFN-a and IFN-γ as well as IL-12 and TNF -at.
The invention also provides a method of inducing protective immunity against a disease in a mammal which comprises administering to a mammal in need of an immunostimulatory amount of a compound of the invention pathological antigen. The include antigens derived from pathogens including viruses, bacteria and protozoa which cause the above infectious diseases. The invention also provides a composition comprising a compound of the invention and a pathological antigen for use in the induction of protective immunity against disease in a mammal.
also provides the use of a comprising a compound of the invention and a pathological antigen in the manufacture of a medicament for the induction of protective immunity against disease in a mammal.
The invention also provides a method of treatment or prophylaxis of cancer in a mammal which comprises administering to a mammal having in conjunction with a pathological antigens
The invention composition
BE2017 / 5621 need an immunostimulatory amount of a compound of the invention together with a cancer antigen. Cancer antigens include antigens associated with or derived from the above-mentioned cancers. The invention also provides a composition comprising a compound of the invention and a cancer antigen for use in the treatment or prophylaxis of cancer in a mammal. The invention also provides the use of a composition comprising a compound of the invention and a cancer antigen in the manufacture of a medicament for the treatment or prophylaxis of cancer in a mammal.
An immunostimulatory amount of a compound of the invention may be between 1 pg and 2 mg, although this amount is illustrative and not limiting. Thus, a vaccine composition can comprise, for example, the antigen and 1 pg to 2 mg of a compound of the invention.
The compounds of the invention are expected to exhibit one or more of the following favorable attributes: good agonist activity at hTLR7 and / or hTLR8 (preferably hTLR7 and hTLR8); a favorable TLR7 / 8 agonist activity report; good activity in the induction of cytokines for example, IFN-a, IFN-γ and / or TNF-a, low toxicity; and good chemical and physical stability.
Throughout the following description and claims, unless the context requires otherwise, the term "understand", and variations such as "includes" and "comprising", will be understood to imply the inclusion of an integer, a step, a group of whole numbers or a group of steps
BE2017 / 5621 indicated but not the exclusion of any other whole number, step, group of whole numbers or group of steps.
Abbreviations p-TsOH p-toluenesulfonic acid p-TsCl p-toluenesulfonyl chloride THP tetrahydropyran TBS t-butyldimethylsilyl HIV human immunodeficiency virus HAV hepatitis A virus HBV hepatitis B virus HCV hepatitis C virus HPV human papillomavirus IFN interferon early lH-tetrazole Lev levulinoyl TEA triethylamine THIS cyanoethyl Imid imidazolium OTf triflate nBu n-butyl i-Pr isopropyl Bn benzyl t-bu t-butyl MeCN acetonitrile Eg equivalent M molar h hour YOUR ambient temperature
BE2017 / 5621
General procedure for the synthesis of compounds of
Examples formula (I)
The compounds of formula (I) according to the general procedure scheme 2 were prepared as shown in the
Diagram 2
A compound of formula (VIII) (2.0 equivalents) and 2-cyanoethyl-N, N, N ', N'-tetraisopropylphosphorodiamidite (2.1 equivalents) were dissolved in anhydrous methylene chloride (0.4 M ) at TA. 1Htetrazole (2.1 equivalents) was added in four parts over 20 min and the reaction mixture was stirred at RT for 1 h. The reaction mixture was cooled to 0 ° C, imidazoquinoline of formula (II) (1.0 equivalent) (1.5 equivalent) and imidazolium triflate were added, and the reaction mixture was allowed to settle. reheat at RT. The reaction was usually completed after 1 h at RT and the reaction mixture was purified by chromatography on silica gel (after reduction of the volume by concentration in vacuo). The resulting phosphite (I *) was dissolved in chloroform (0.07 M) and oxidized by
BE2017 / 5621 ° C and stirred (10.0 equivalents) aqueous treatment, the addition of t-butyl hydroperoxide (1.5 equivalents).
After stirring at RT for 30 min, the reaction mixture was concentrated in vacuo. The levulinoyl group was then deprotected by reaction of (I *) in a pyridine / acetic acid 4/1 mixture (0.05 M) with hydrated hydrazine (5.0 equivalents). After 5-10 min at RT, the reaction mixture was cooled to with 2,4-pentanedione at 0 ° C for 5 min. After the dried crude product was dissolved in acetonitrile (0.06 M). Triethylamine (acetonitrile / TEA 1 / 0.35 v / v) was added and the reaction mixture was stirred at RT for 6 to 18 h. After complete deprotection, the reaction mixture was filtered through a Büchner filter and the isolated solid was rinsed with acetonitrile and dried under high vacuum, or purified by chromatography on silica gel to give the compound of formula I.
Example 1 "% $
, x
MS
SK.
M t)
Λ »** · ⁷ ···. "'
MS
This compound was prepared following the method of scheme 3.
BE2017 / 5621 a · _ν - 3 iilii / ÈI jis'V s5 "M,", * âS! Easfo raiwir
ÎS,, À_-i.
[M
.. · * Τλ Vs. îBBlî ^S '3S' j
ÈJfîTStiïï flSÎS »» îï
BÏ ^ K * "ft"
Diagram 3
Cl was coupled with 1,2-dioleoyl-sn-glycerol following the procedure described in general procedure 1. After purification by chromatography on silica gel (0 to 10% methanol in chloroform), the phosphite (I *) corresponding was isolated in a yield of 66%. (I *) was then oxidized with t-butyl peroxide and deprotected sequentially with hydrated hydrazine and TEA as described in general procedure 1 to give Example 1 in 84% yield. NMR (400 MHz, CDCI3 / CD3OD) δ 7.84 (d, 1H), 7.24 (m, 2H), 5.33 (m, 4H), 5.27 (m, 1H),
4, 8 (m, 2H), 4.43 (dd, 1H), 4.39 (m, 2H), 4.22 (dd, 1H), 4, 10 (t, 2H), 3.99 (t, 2H), 2, 92 (t, 2H), 2.32 (m, 4H), 2, 00 (m, 8H), 1.84 (m, 2H), 1.60 (m, 4H), 1.51 (m, 2H),
1.30 (m, 40H) 1.02 (t, 3H), 0.88 (m, 6H); TOF-MS ES negative, calculated for [M-H] ~ 1025.67, found 1025.72.
BE2017 / 5621
Example 2
x .... ....
âæwtar w Y
Ws yyV
This compound was prepared following the method of scheme 4.
"
W · "i
 ..,. $ ISfcjgïjï æ
<& ÎS33üïï
ΤΎ susse
Mr.
M yFy.,
088
Me
I ⁵ yï
Diagram 4
Cl was coupled with 1,2-dipalmitoyl-3triethylene glycol-sn-glycerol following the procedure described in general procedure 1. After purification by chromatography on silica gel (0 to 10% methanol in chloroform), the phosphite (I *) correspondent was not isolated clean. The gross (I *) has
BE2017 / 5621 was then oxidized with t-butyl peroxide and the resulting oxidized (I *), obtained in a yield of 51% after purification by chromatography on silica gel (0 to% methanol in chloroform), was sequentially deprotected with hydrated hydrazine and TEA as described in general procedure 1 to give Example 2 in a yield of 61% after chromatography on silica gel (0 to 40% of methanol
in chloroform ). NMR! H (400 MHz, CDCI3 / CD3OD) δ 7.79 10 (d, 1H), 7.11 (bs, 2H), 5.21 (m, 1H), 4.49 (t, 2H), 4.34 (m, 5H), 4.07-4.16 (m, 3H), 4.01 (t, 2H), 3.72 (t, 2H),
1107.6374.
3.60-3.66 (m, 11H), 2.91 (t, 2H), 2.30 (dd, 4H), 1.82 (m, 2H), 1.60 (m, 4H), 1 , 50 (m, 2H), 1.25 (m, 45H), 1.01 (t, 3H), 0.88 (t, 6H); TOF-MS ES positive, calculated for [M + H] ⁺ 1107.7338, found
Example 3
Ms.
This compound was prepared by following the method of scheme 5.
BE2017 / 5621, -> .. Αγ inr iâ®8W5î »SSsSWî« ''xh'K _s
Diagram 5
1-palmitoyl-2C1 was coupled with tetrahydropyranyl-sn-glycerol following the procedure described in general procedure 1. After purification by chromatography on silica gel (0 to 10% methanol in chloroform), the phosphite (I *) corresponding was isolated in a yield of 34%. (I *) was then oxidized with t-butyl peroxide and deprotected sequentially with hydrated hydrazine and TEA as described in general procedure 1 to give the intermediate protected by a corresponding THP group in a 85% yield. The THP protecting group was removed by reaction in chloroform / methanol (1/1, 0.02 M) with
4 N HCl / dioxane (2.5 equivalents) at 0 ° C for 3 h. After 3 h, the reaction mixture was dried under vacuum and purified by chromatography on silica gel (0 to 25% methanol / water 95/5 in chloroform) to give Example 3 in a yield of 92%. NMR ^: Η (400 MHz, CDCI3 / CD3OD) δ 7.85 (d, 1H), 7.26 (m, 2H), 5.34 (m, 2H), 4.50 (m, 4H), 4, 39 (m, 2H), 4.13 (m, 2H), 4.02
BE2017 / 5621
5H), 2, 91 (t, 2H), 2.32 (t 2H), 1.60 (m, 2H), 1.50 (m, 3H), 0.88 (t, 3H); TOF- MS
[M-Η] ^- 761.91, found 761.71
Example 4 ί ^x - / »S * SSI 'SS'
This compound was prepared following the method of scheme 6.
>; - Ηί · πΕΗΗ
HKj - / s ίΓ; if, xi] < ^A jA
Λ · ¹ '· »
SSSSSSSSSSSSI1.
ίΜβί ^ ΐμ ": ·· '"
IR!
-. „. ÄH-srereBiwr •’ anrnsnaw-f-M, ^ · ^ a * .JL
-TSîff 's'
Î'f.mii'iŒ
.................
w:
Diagram 6
Cl was coupled with triethylene glycol cholesterol following the procedure described in general procedure 1. After purification by chromatography on silica gel (0 to 10% methanol in chloroform), the corresponding phosphite (I *) was isolated in a yield of 37%. (I *) was then oxidized with
BE2017 / 5621 t-butyl peroxide and after purification by chromatography on silica gel (0 to 10% methanol in chloroform), the oxidized phosphite (obtained in a yield of 53%) was sequentially deprotected with hydrazine hydrated and TEA as described in general procedure 1 to give Example 4 in a yield of 71%. NMR ^: Η (400 MHz, CDCI3 / CD3OD) δ 7.71 (d, 1H), 6.95 (bs, 2H), 5.30 (m, 1H), 4.47 (m,
2H), 4.24 (bs, 4H), 4.07 (m, 2H), 4.02 (m, 2H), 3.71 (t,
2 H), 3, 63-3, 66 (m, 9H contains H2O), 3.15 (m, 1H), 2.91 (t, 2H), 2.33 (dd, 1H), 2.18 ( t, 1H), 1.77-2.00 (m, 7H), 1.20-1.68 (m, 20H), 0.81-1.15 (m, 23H), 0.65 (s, 3H);
TOF-MS ES negative, calculated for [M-H] ~ 923.5663, found 923, 6067.
Example 5 its
You're
This compound was prepared following the method of scheme 7.
BE2017 / 5621
SSE 'YSKHSSBiTS îbjiîum'es î T'V- "® âi .. <. • -’ ’' χ. :. • ’" χ, • "'i vJCR
AlO!) & SUSâsÆsS »WS!
.................................................. ............................................ ..J * irV ' f
Υ'-φγ / Ο '
Tallinn HR!
Diagram 7
C2 was coupled with 1,2-dioleoyl-sn-glycerol following the procedure described in general procedure 1. After purification by chromatography on silica gel (0 to 10% methanol in chloroform), the phosphite (I *) corresponding was isolated in a yield of 74%. (I *) was then oxidized with t-butyl peroxide and deprotected sequentially with hydrated hydrazine and TEA as described in general procedure 1 to give Example 5 in a yield of 79% after chromatography on silica gel (0 to 15% methanol / water 95/5 in chloroform). IH NMR (400 MHz, CDCI3 / CD3OD) δ 7.90 (d,
1H), 7, 65 (s, 1H), 7.02 (d, 1H), 5.34 (m, 4H), 5.26 (m, 1H), 4.58 (t, 2H), 4.41 (dd, 1H), 4.29 (t, 2H), 4.19 (dd, 1H), 4.1 (m, 4H), 4.00 (t, 2H), 2.98 (t, 2H), 2.30 (m, 4H), 2.00 (m, 10H) , 1.89 (m, 2H), 1.80 (m, 2H), 1.58 (m, 4H), 1.51 (m, 2H), 1.29 (m, 40H), 1.03 (t, 3H), 0.88 (m,
6H); TOF-MS ES negative, calculated for [M-H] ~ 1053.7027, found 1053.7857.
BE2017 / 5621
Example 6
NH <5>^; u • I yn & s
I 1>
AA a i X <sa / & Ur This compound was prepared following the procedure of scheme 8.
HC '''' ^x j ' ^x C ^r -üléoyle D-ûléoylé; ///// tetrazole «v-irjx ·
..... I ..........
I ij-olerv-le O-oléoyle
d. xivCjÇ . 2.: -. && <& {ί ϊ £ · ί ......
Olèoyi-O
O-oleoyl
Example. 6
Diagram 8
C3 was coupled with 1,2-dioleoyl-sn-glycerol following the procedure described in general procedure 1. After purification by chromatography on silica gel (0 to 10% methanol in chloroform), the phosphite (I *) corresponding was isolated in a yield of 75%. (I *) was then oxidized with t-butyl peroxide and deprotected sequentially with hydrated hydrazine and TEA as described in general procedure 1 to give Example 6 in a yield of 80% after chromatography on silica gel (0 to 15% methanol / water 9/1 in
BE2017 / 5621
chlo: rotor: me). NMR ^: H (4 00 M Hz, CDCls / CD3OD) δ 7, 91 (d, 1H), 7.4 7 (s, 1H), 7.07 (d, 1H), 5.34 (m, 4H), 5.27 (m, 1H), 4.58 (t, 2H), 4.42 (dd, 1H), 4.35 (t, 2H), 4.21 (dd, 1H), 4.10 (m, 4H), 4.01 (t, 2H), 3.94 (t, 2H), 3.76 (t, 2H), 3.72 (t, 2H), 3.64 (t, 2H), 2.98 (t, 2H), 2.31 (m, 4H), 2.01 (m, 8H), 1.88 (m, 2H), 1.50 (m, 6H), 1.29 (m,
40H), 1.03 (t, 3H), 0.88 (m, 6H); TOF-MS ES negative, calculated for [MH] ^- 1113.7232, found 1113.8110.
Example 7
This compound was prepared by following the method of scheme 9.
ÎK ”h K il
I live
TïJ- · »
XJ t
SfS _s . ..!
: * s »irr» ®> H! »sa a rr v.®
X -psgJ t,
... g "s ^x " Μ "ϊβγ"
Diagram 9
BE2017 / 5621
Cl was coupled with 1,2-dipalmitoyl-sn-glycerol following the procedure described in general procedure 1. After purification by chromatography on silica gel (0 to 12% methanol in chloroform), the phosphite (I *) corresponding was isolated in a yield of 67%. (I *) was then oxidized with t-butyl peroxide and deprotected sequentially with hydrated hydrazine and TEA as described in general procedure 1 to give Example 7 in a yield of 68% after purification by chromatography on silica gel (0 to 15% methanol / water 9/1 in chloroform). NMR ^: Η (400 MHz,
CDCI3 / CD3OD) δ 7.83 (d, 1H), 7.26 (m, 2H), 5.26 (m, 1H), 4.50 (m, 7H), 4.21 (dd, 1H), 4.09 (t, 2H), 4.00 (t, 2H), 2.91 (t, 2H), 2.31 (m, 4H), 1.83 (m, 2H), 1.5 (m, 6H), 1.25 (m, 48H) , 1.02 (t , 3H) 0.8 8 (m, 6H); TOF- MS ES
negative, calculated for [M-H] ~ 973.64, found 963.65.
Comparative example 1
Os î '
This compound was prepared following a procedure known from the literature (Gerster et al. J. Med. Chem., 2005, 48, 3481).
BE2017 / 5621
Comparative example 2
vYk -U ..............o Mid M
This compound was prepared following the method of scheme 10.
iffl'i iLyiJs
ÎF3TOHÏÏT3
Y '3H3ÏÏ35E
............... v · '' ¹ - '· fiï «iiii
A> 'S'
....................., ............ ^ liii η
2223; sk
9bïS _ 1 to
SÎSÎB3 sBX ^{: r} '·· H wf * Ύ
1ŒO5E
Figure 10
Di-oleoyl-sn-glycerol (2.0 equivalents) and 2cyanoethyl-N, N, N ', N'-tetraisopropylphosphorodiamidite (1.5 equivalents) were dissolved in anhydrous chloroform (0.4 M) at RT . 1H-tetrazole (1.5 equivalent) was added in four parts over 20 min and the reaction mixture was stirred at RT for 2 h. The reaction mixture was cooled to 0 ° C, from Example
Comparative BE2017 / 5621 1 (1.0 equivalent) and imidazolium triflate (2.0 equivalent) were added, and the reaction mixture was allowed to warm to RT. The reaction was complete after 1 h at RT and the reaction mixture was purified by chromatography on silica gel (0 to 15% methanol in chloroform) to give the corresponding phosphite in a yield of 92%. The phosphite was dissolved in chloroform (0.07 M) and oxidized by the addition of tbutyl hydroperoxide (2.0 equivalents). After stirring at RT for 30 min, the reaction mixture was concentrated in vacuo. The dried crude product was dissolved in acetonitrile (0.08 M). Triethylamine (acetonitrile / TEA 1 / 0.35 v / v) was added and the reaction mixture was stirred at RT for 15 h and then dried under vacuum. Purification by chromatography on silica gel (0 to 15% methanol in chloroform) gave Comparative Example 2 in a yield of 75%. NMR ^: Η (400 MHz, CDCI3 / CD3OD) δ 8.18 (bs, 1H), 7.39 (bs, 1H), 7.18 (bs, 1H), 6.92 (bs, 1H), 5, 33 (m, 4H), 5.25
(m, 1H), 4.80 (bs, 2H), 4.60 (bs, 2H), 4.41 (dd, J = 3.2, 12, 0 Hz, 1H), 4.19 (dd, J = 6.4, 12.0 Hz, 1H), 4, 03 (t, J = : 6, 0 Hz, 2 H), 3.01 (bs, 2H), 2.30 (m, 4H), 1, 98 (m, 4H) , 1.5 7 (m, 6H), 1.27 (m, 40H), 1.05 (t, J = 7.2 , 3H), 0.8 8 (m, 6H) ; TOF-MS ES negative, calculation .é pour [M-H] -
965.6497, found 965.6498.
Comparative example 3
BE2017 / 5621 fis f I 5 ......
/ ΧρΛζ * 'x
MID.
This compound was prepared following the method of scheme 11.
he·
...................
llll
,. · / <. .23¾ f,
..- 1. Â, J if V '"r ^s - * i''> · TO ^s ' ·
S3 »
3® sass ÎSM3 "srav uMUrarE Q" V *. asa ^ ssiâ
T I sst "sa, ®
... V. ··· -y M9BUB
JS ,.
w.
Ί ws ^: £ ï>
l; * '·
S:
I <8Î
Figure 11
Concentrated nitric acid (70% content, 1.5 equivalents) was added very slowly to a solution of C4 in propionic acid (0.37 M)
heated to 125 ° C. The reaction mixture at summer restless for 3 hrs at 125 ° C, allowed to cool to YOUR and filtered on paper filtered. The solid collected at summer rinsed
with water and dried under vacuum to give C5 in a yield of 74%.
A solution of POCI3 (1.2 equivalent) in DMF (1.6 M), prepared by the dropwise addition of POCI3 to cold DMF (0 ° C) and stirring for 30 min at 0 ° C,
BE2017 / 5621 was added slowly to a suspension of C5 in DMF (0.45 M). At the end of the addition, the reaction mixture was heated at 100 ° C for 5 min, cooled to RT and poured into ice water. The resulting precipitate was filtered and dried in vacuo overnight. The dried solid was dissolved in chloroform (0.4 M) and TEA (1.4 equivalent) and ethanolamine (1.2 equivalent) were added and the reaction mixture was stirred at 40 ° C for 1 h then at RT for 4 h. The reaction mixture was concentrated in vacuo, and the dried solid was washed with water, filtered, dried, triturated with hot ethyl acetate to give C6 in a yield of 94%. NMR (400 MHz, CDsOD) δ 9.31 (s, 1H), 8.22 (d, 1H), 7.3 (m, 6H), 7.17 (dd, 1H), 5.23 (s, 2H), 4.05 (t, 2H), 3.85 (t, 2H).
C6 was dissolved in a 1/1 solution of chloroform / methanol (0.01 M) and hydrogenated with 10% Pd / C using an H-Cube from ThalesNano (total H2, 40 to 60 ° C). The hydrogenated solution was concentrated, dried in vacuo and purified by chromatography on silica gel to give C7 and C7a in a yield of 21% and 41%, respectively. C7: LC-MS [M + H] ⁺ 310.13; C7a: LC-MS [M + H] + 220.08.
P-TsOH (0.2 equivalent) was added to a suspension of C7a in toluene (0.15 M) and the suspension was heated to 60 ° C. Trimethyl orthovalerate (2 equivalents) was added dropwise and the mixture was stirred at 60 ° C for 5 h cooling to RT, the reaction mixture
After was concentrated, dried under vacuum and purified by
BE2017 / 5621
Chromatography on silica gel (5 to 40% methanol in chloroform). The fractions containing the desired product were dried and recrystallized from chloroform / methanol / ethyl acetate to give C8 in a yield of 42%.
Cesium carbonate (3 equivalents) was added to a solution of C8 in DMF (0.18 M) at 0 ° C. A solution of bromoethanol protected by an acetyl group in DMF (1.2 equivalent, 1.3 M) was then added dropwise and the reaction mixture was stirred at 0 ° C for 10 min then allowed to warm to RT . After stirring overnight at RT and aqueous treatment, the dried crude product was purified by chromatography on silica gel (0 to 15% methanol in chloroform) to give C9 in a yield of 77%.
Peracetic acid (1.2 equivalents) was added to a suspension of C9 in ethanol reagent (0.08 M) and the reaction mixture was heated at 60 ° C for 2.5 h. Additional peracetic acid (0.1 equivalent) was added and the reaction mixture was heated at 60 ° C for a further 6 h. After concentration and drying under vacuum, the crude product was purified by chromatography on silica gel (0 to 35% of methanol in chloroform) to give the corresponding N-oxide intermediate in a yield of 73%. P-TsCl (1.1 equivalent) was added slowly to a suspension of N-oxide in aqueous concentrated ammonia (0.3 M) and the reaction mixture was stirred at RT for 30 min. More p-TsCl (0.9) was added and after 30 min at RT, the reaction mixture was neutralized with water. After aqueous treatment,
BE2017 / 5621 the crude product was purified by chromatography on silica gel (0 to 25% methanol in chloroform) to give Comparative Example 3 in the form of an off-white solid in a yield of 46%. NMR
5 (400 MHz, CDsOD) δ 8.25 (d, 1H), 7.28 (m, 2H), 4.78 (t, 2H), 4.21 (t, 2H), 4.03 (t, 2H), 3.95 (t, 2H), 3.16 (t, 2H), 1.98 (m, 2H), 1.56 (m, 2H), 1.05 (t, 3H) ; TOF-MS ES positive, calculated for [M + H] ⁺ 345, 1927, find
345.2241.
Comparative example 4
AT.
• Z
Λ
This compound was prepared in scheme 12.
according to the process of
98IS5 .ζν.ζ ·· 1.- · ΜΚ5 ass ifîlIKHÏEH f i [I jist iiiiiiiii '1 * tf <: «o
Γ A llill
SSSilH ï2is «S
VS
.............................. Di ..... il ......... i ... ....................
nr 4 ïçp: SSBS5
.................................................. .............
f; j) ^ -sæ. m yr Ί
SBIS!
Did OJ t.
iii s ": <
llilill i * ’·
223SÏ
Figure 12
BE2017 / 5621
P-TsOH (0.2 equivalent) was added to a suspension of C7 in toluene (0.15 M) and the suspension was heated to 60 ° C. Trimethyl orthovalerate (2 equivalents) was added dropwise and the mixture was stirred at 60 ° C for 5 h. More trimethyl orthovalerate was added as needed to push the reaction to completion. After cooling to RT, the reaction mixture was filtered, the precipitate was washed with ethyl acetate and dried to give IOC as a light brown solid in a yield of 97%.
Levulininic acid (1.2 equivalents) was added to a suspension of IOC in anhydrous methylene chloride (0.27 M). The reaction mixture was cooled to 0 ° C and DMAP (0.02 equivalent) and DCC (1.05 equivalent) were added. After 10 min at 0 ° C followed by 40 min at RT, the reaction mixture was adsorbed on silica gel and purified by chromatography on silica gel (0 to 8% methanol in chloroform) to give C11 in a yield 66%.
Peracetic acid (1.2 equivalents) was added to a suspension of C11 in ethanol reagent (0.16 M) and the reaction mixture was heated at 60 ° C for 3 h. After concentration and drying under vacuum, the crude product was triturated with hot ethyl acetate, filtered and dried to give the corresponding dioxide intermediate in a yield of 83%. Aqueous ammonia (ammonia / methylene chloride 1/3) was added to a solution of N-oxide in chloride
BE2017 / 5621 methylene (0.2 M). P-TsCl (1.1 equivalent) was added slowly and the reaction mixture was stirred at RT for 30 min and then neutralized with water. After aqueous treatment, the crude product dissolved in chloroform / methanol 1/1 was hydrogenated on 10% Pd / C using an H-Cube from ThalesNano (60 ° C, total H2 mode). The hydrogenated solution was concentrated, dried under vacuum, and purified by chromatography on silica gel (0 to 15% methanol in chloroform) to give C12 in a yield of 88%.
Cesium carbonate (3 equivalents) was added to a solution of C12 in DMF (0.2 M) at 0 ° C. A solution of bromobutanol protected by TBS in DMF (1.2 equivalent, 1.3 M) was then added dropwise and the reaction mixture was stirred at 0 ° C for 10 min then at RT for 7 h then neutralized with water. After aqueous treatment, the dried crude product was purified by chromatography on silica gel (0 to 10% methanol in chloroform) to give C13 in a yield of 78%.
A solution of C13 in chloroform / methanol 1/1 (0.016 M) was hydrogenated on 10% Pd / C using an H-Cube from ThalesNano (TA, total H2 mode). The hydrogenated solution was concentrated, dried under vacuum, and purified by chromatography on silica gel (0 to 15% methanol in chloroform) to give C14 in a yield of 66%.
A solution of C14 in a mixture of pyridine / acetic acid 4/1 (0.05 M) was reacted with hydrated hydrazine (5.0 equivalents). After 5 to 10 min at RT, the reaction mixture was cooled to 0 ° C and
BE2017 / 5621 stirred with 2,4-pentanedione (10.0 equivalents) at ° C for 5 min. After aqueous treatment, the dried solid was salted with concentrated HCl and recrystallized from methanol / ethyl acetate to give Comparative Example 4 in a yield of 78%. NMR ^: Η (400 MHz, CDsOD) δ 8.20 (d, 1H), 7.21 (m, 2H), 4.70 (t,
2H), 4.17 (t, 2H), 4.01 (t, 2H), 3.65 (t, 2H), 3.05 (t,
2H), 1.93 (m, 4H), 1.75 (m, 2H), 1.54 (hex, 2H), 1.04 (t, 3H), TOF-MS ES positive, calculated for [M + H] ⁺ 345.1927, found 345.2241.
Comparative example 5
AT-**
This compound was prepared following the method of scheme 13.
f γΛ AA '' sssa
Figure 13
BE2017 / 5621
Cesium carbonate (3 equivalents) was added to a solution of C12 in DMF (0.1 M) at 0 ° C. A solution of triethylene glycol bromide in DMF (1.2 equivalent, 1.3 M) was then added dropwise and the reaction mixture was stirred at 0 ° C for 10 min then at RT for 17 h then neutralized with water. After aqueous treatment, the dried crude product was purified by chromatography on silica gel (0 to 30% methanol in chloroform) to give Comparative Example 5 in a yield of 13%. NMR ^: Η
(400 MHz, CDsOD) δ 8.20 (d, 1H), 7.21 (m, 2H), 4.70 (t, 2H), 4, 17 (t, 2H), 4.01 (t, 2H), 3.65 (t, 2H), 3.05 (t, 2H), 1, 93 (m, 4H), 1.75 (m, 2H) , 1.54 (hex, 2H), 1.04 (t, 3H); TOF-MS ES positive, calculated for [M + H] ⁺ 433, 2451, found 433.2816.
Intermediate Cl
This compound was prepared following the method of scheme 14.

Figure 14

Cesium carbonate (6 equivalents) was added to a solution of C12 in DMF (0.11 M) at 0 ° C. A solution of bromoethanol protected by a TBS group in DMF (1.2 equivalent, 0.4 M) was then added dropwise and the reaction mixture was stirred at
BE2017 / 5621 ° C for 10 min then allowed to warm to RT. After stirring at RT or 5 h and aqueous treatment, the dried crude product was purified by chromatography on silica gel (0 to 5% methanol in chloroform) to give C14 in a yield of 59%. LC-MS: [M + H] ⁺ 557.3.
TFA equivalents were added to a solution of C14 in methylene chloride (0.18 M) and the reaction mixture was stirred at RT for 4 h. After
drying underon gelchloroform)yield of ; vacuum and purification by chromatographysilica (0 to 20% methanol in, Cl (TFA salt) was obtained in a83%. Formulations watery I. ScreeningFor saltsimprove the solubility of derivatives
imidazoquinoline (IQ) lipids described here, a salt screening study was carried out. For this study, the acid salts tested included naphthalene-1,5-disulfonic acid; benzenesulfonic acid; HCl; 2-naphthalenesulfonic acid. The basic salts tested included choline bicarbonate, choline hydroxide, TRIS; ethylene diamine; and N-methylglucamine.
With the exception of the choline salts, none of the salts tested had a significant effect on the solubility of the compound IQ. In addition, LCMS found that the choline salt forms of IQ generally showed less degradation during the drying process than the others.
BE2017 / 5621 salts tested. Based on the results of the salt screening, the choline bicarbonate and choline hydroxide salts were chosen for the development of another formulation process.
II. Salting process with choline
During the salt screening experiments described above, it was observed that the solvent removal steps could impair the recovery of the salty IQ compound. Specifically, the increase in drying times resulted in lower solubility and increased degradation of the IQ compound. It was surprisingly found that acceptable solubility and stability could be obtained either by avoiding the use of organic solvents (direct aqueous salting process), or by reducing the drying time required to remove the solvent ( dry salting process). FIG. 18 is a schematic representation of the salting process of the prior art (A), and of the two new salting processes (B - Direct aqueous process; C - Dry salting process).
A. Initial salting process
The salts of the IQ compounds were prepared according to methods known in the art. In short, the lipid imidazoquinoline derivatives (IQ) are dissolved in tetrahydrofuran (THF). The acid or base salts are dissolved in methanol, and added to the dissolved IQ. The solvents are then removed by evaporation using a rotary evaporator, this followed by additional drying under high vacuum at temperature.
BE2017 / 5621 ambient for 1 to 19.5 hours. After the solvents have evaporated, a 2% solution of glycerol in water is added to the salted compound and sonicated for 15 minutes with a probe sonicator. The salted formulation is then sterilized by filtration with a 0.22 µm syringe filter. The concentration of the IQ salts is determined by RP-HPLC, and the identity of the product is confirmed by liquid chromatography-mass spectrometry (LCMS).
B. Direct aqueous salting process
The salts of the compounds of Examples 1 to 7 were prepared according to the following methods. First, the lipidated imidazoquinoline derivative (IQ) was dissolved directly in an aqueous vehicle (2% glycerol in water). A choiine salt, either choiine bicarbonate or choiine hydroxide, was added directly to compound IQ dissolved in amounts of 0.6, 0.8, 1 and 1.2 molar equivalents (EQ). The solution was then sonicated for 15 to 90 minutes with a probe sonicator at a temperature of 60 to 80 ° C. The salted formulation was sterilized by filtration with a 0.22 µm syringe filter.
The salt salts of the compounds of Examples 1 to 7 were at least as soluble as the compounds prepared by the salting procedure of the prior art, but, surprisingly, they exhibited significantly less degradation than the salts of IQ prepared by the process of the prior art. In addition, the direct aqueous process can be carried out in less time than the process of the prior art, and avoids the use of organic solvents. Similar results were
BE2017 / 5621 observed for salted compounds made with 0.6, 0.8 and 1.2 EQ of choline salts. These results indicate that direct aqueous salting is an advantageous method for use with the IQ compounds described herein.
C. Dry salting process
The salts of the compounds of Examples 1 to 7 were prepared according to the following methods. First, the lipidated imidazoquinoline derivative (IQ) was dissolved in tetrahydrofuran (THF). A choline salt, either choline bicarbonate or choline hydroxide, was added directly to the dissolved IQ compound in amounts of up to 4 molar equivalents (EQ). The THF solvent was then removed by evaporation using a rotary evaporator. No vacuum drying was carried out. After evaporation of the solvent, a 2% solution of glycerol in water was added to the salted compound and sonicated for 15 minutes with a probe sonicator. The salted formulation was then sterilized by filtration with a 0.22 µm syringe filter.
It has been found that the choline bicarbonate and choline hydroxide salts of the compounds of Examples 1 to 7 have better solubility and better stability compared to the unsalted formulation, indicating that the dry salting process is an advantageous process for a use with the IQ compounds described here.
BE2017 / 5621
Biological data
Processes
Analysis of the agonist activity of hTLR7 and hTLR8 in HEK-293 cells
The determination of TLR agonist activity was carried out using the HEK293 binding test. This test measures the selectivity and the potency for TLR7 and TLR8 of the compounds tested. HEK293 cells expressing human TLR7 or TLR8 and the reporter gene for NFkB-sensitive embryonic secreted alkaline phosphatase (SEAP) were obtained from InvivoGen (San Diego, CA). These cells were maintained in culture medium, Eagle medium modified by Dulbecco (DMEM) (Invitrogen, Grand Island, NY), 10% fetal bovine serum (FBS) (Sigma, St. Louis, Missouri) and selection antibiotics (Invitrogen, and Invivogen). HEK293 stably transfected with human TLR7 (hTLR7) or human TLR8 (hTLR8) were stimulated for 24 h with aqueous formulations of the test compounds and the culture supernatants were analyzed for activation of NFkB using the SEAP QuantBlue colorimetric detection kit (InvivoGen).
Tests to measure induction of cytokines
The test compounds were evaluated for the induction of cytokines in human peripheral blood mononuclear cells (hPBMC).
HPBMC preparation
Primary human PBMCs have been isolated from fresh blood from healthy donors via
BE2017 / 5621 of a Ficoll gradient separation and deposited at
0.5 x 10 ⁶ cells / well in 96-well tissue culture plates (RPMI-1640 plus 10% FBS). The hPBMCs were maintained with the culture medium RPMI5 1640 (Invitrogen, Grand Island, NY), antibiotics (Invitrogen) and 10% FBS (Sigma).
Incubation and tests for IFN-γ, IFN-α and TNFa
The hPBMCs were stimulated for 24 h with aqueous formulations of the test compounds. The culture supernatants were analyzed for the induction of TNF-α and IFN-γ using multiplex kits (FluoroKine multiplex kits from R&D Systems, Minneapolis, MN) and for the induction of IFN-α using the ELISA kit for IFN-α VeriKine (Pestka Biomedical Laboratories, Inc., Piscataway, NJ).
Results
Comparative Examples 1, 2 and 3 and Example 1 were tested for their hTLR7 and hTLR8 agonist activity and the results are presented in Figures 1 and 2 and summarized in Table 1 below.
Table 1
E.g. comp. 1 E.g. comp. 2 Ex.comp. 3 Ex. 1 DE50 for thehTLR7 (μΜ) 0.58 34.58 1.56 1.06 DE50 for thehTLR8 (μΜ) 0.19 25, 99 0.10 0.10 reporthTLR7 / 8 3.1 1.3 15.5 11.0
BE2017 / 5621
The results show that Example 1 demonstrates significant selectivity for hTLR8 / hTLR7 and is significantly more potent as an agonist of hTLR7 and hTLR8 than Comparative Example 2 in this reporter test.
On another occasion, Comparative Examples 1, 2 and 3 and Examples 1, 3 and 4 were tested for their agonist activity of hTLR7 and hTLR8 and the results are presented in Figures 3 and 4 and summarized in Table 2 below.
BE2017 / 5621
Table 2
Ex.comp. 1 Ex.comp. 2 Ex.comp. 3 Ex. 1 Ex. 3 Ex. 4 DE50 for thehTLR7 (μΜ) 1.0 55.4 * 2.4 7.0 3.4 DE50 for thehTLR8 (μΜ) 0.4 39.2 * 0.8 0.8 2.8 31.9 reporthTLR7 / 8 2.3 1.4 2.9 8.9 1.2
* only very low NFkB activation rates have been detected
The results confirm that Example 1 is more active than Comparative Example 2 as an agonist of hTLR7 and hTLR8. Example 3 is also a potent hTLR7 and hTLR8 agonist, approximately equally potent at both receptors in this reporter assay. Example 4 was a weaker hTLR8 agonist and did not have an agonist effect on hTLR7 in this reporter test.
On another occasion, comparative examples 1, 3, 4 and 5 and examples 1, 5, and 6 were tested for their agonist activity of hTLR7 and hTLR8 and the results are presented in FIGS. 5 and 6 and summarized in Table 3 below.
BE2017 / 5621
Table 3
Ex.comp. 1 Ex.comp. 3 Ex.comp. 4 Ex.comp. 5 Ex . 1 Ex. 5 Ex. 6 DE50for thehTLR7(μΜ) 1.1 2.2 1.6 13.2 4, 1 10.5 * 8.7 * DE50for thehTLR8(μΜ) 0.72 1.1 2.2 16.3 0, 59 6.6 * 5, 8 reporthTLR7 / 8 1.5 1.9 0.7 0.8 6, 9 1.6 1.5
* only very low NFkB activation rates have been detected
The results confirm that Example 1 is an agonist of both TLR7 and TLR8.
Example 5 was a very weak hTLR7 or hTLR8 agonist in this reporter test. Comparative Example 4 was a good hTLR7 and hTLR8 agonist but Comparative Example 5 was a rather weak hTLR7 and hTLR8 agonist in this reporter test. Example 6 was a reasonably potent hTLR8 agonist in this reporter assay, but was a very weak hTLR7 agonist in this reporter assay.
On another occasion, Comparative Example 1 and Examples 1, 2, and 7 were tested for their agonist activity of TLR7 and TLR8 and the results are presented in Figures 7 and 8 and summarized in Table 4 below. below.
BE2017 / 5621
Table 4
E.g. comp. 1 Ex. 1 Ex. 2 Ex. 7 DE50 for thehTLR7 (μΜ) 1.5 7.0 6.1 14.6 DE50 for thehTLR8 (μΜ) 0.61 0.71 0.81 3, 81 reporthTLR7 / 8 2.4 9, 9 7.5 3, 8
The results for Example 1 were similar to those presented in Tables 1, 2 and 3 above. Example 2 showed a profile similar to that of Example 1 in that it was significantly more potent as an agonist for hTLR8 than for hTLR7. Example 7 was also an hTLR7 and hTLR8 agonist but less potent than Examples 1 and 2, particularly at the hTLR8 level.
Comparative Examples 1, 2 and 3 and Example 1 were tested for their activity in the induction of IFN-γ and IFN-a in hPBMC and the results are presented in Figures 9 and 10 .
Example 1 was more powerful than Comparative Example 3 but less powerful than Comparative Example 1 in the induction of IFN-γ in this test. Comparative example 2 did not induce any IFN-γ in this test.
Example 1 and Comparative Example 3 were equivalent in the induction of IFN-a and these were more potent than Comparative Example 1 and Comparative Example 2 in this test at a lower dose.
On another occasion, Comparative Examples 1, 2 and 3 and Examples 1, 3 and 4 were tested for
BE2017 / 5621 their activity in the induction of IFN-γ, IFN-α and TNF-a in hPBMC and the results are presented in FIGS. 11, 12 and 13.
Examples 1 and 3 were powerful in inducing IFN-γ and each was more powerful than Comparative Example 3 in this test. Comparative example 1 was the most powerful in the induction of IFN-γ in this test. Example 4 and Comparative Example 2 did not induce IFN-γ in this test.
Example 4 was very powerful in inducing IFN-α at a higher dose, being significantly more powerful than Examples 1 and 3 in this test. These three compounds of the examples were all more powerful in the induction of IFN-α than the comparative examples 1, 2 and 3 in this test. The results for Example 4 were interesting considering that this compound was not active in the reporter test for hTLR7 in HEKs. It could be that this compound transmits signals preferentially by the IRF-7 pathway.
Examples 1 and 3 and Comparative Example 3 were all powerful in inducing TNF-α in this test. Comparative example 1 was also powerful in the induction of TNF-α in this test. Comparative Example 2 and Example 4 were not significantly effective in inducing TNF-a in this test.
On another occasion, Comparative Examples 1, 3, 4 and 5 and Examples 1, 5 and 6 were tested for their activity in the induction of IFN-α and TNF-a
BE2017 / 5621 in hPBMC and the results are presented in Figures 14 and 15.
Example 1 was very effective in inducing IFN-α in this test, and Example 6 was as powerful, but less than Example 1. Example 5 was powerful but at one higher dose. The weaker effects are demonstrated for Comparative Examples 1 and 3. Comparative Examples 4 and 5 did not induce IFN-a in this test.
Example 1 and Comparative Examples 1, 3 and 4 were effective in inducing TNF-α in this test. Comparative Example 5 and Example 6 were effective but less powerful. Example 5 showed a very weak effect in this test.
On another occasion, Comparative Example 1 and Examples 1, 2 and 7 were tested for their activity in the induction of IFN-α and TNF-a in hPBMC and the results are presented in the figures. 16 and 17.
Examples 1, 2 and 7 demonstrated good activity in the induction of IFN-α with Example 2 being the most powerful inducer of IFN-α. Comparative example 1 induced little IFN-a.
Examples 1 and 7 and Comparative Example 1 showed similar potency in the induction of TNF-a. Example 2 was a weaker inducer of TNF-a.
The results described here show that the compounds of the invention are effective as agonists of hTLR7 and / or hTLR8 and in the induction of cytokines and are therefore expected to have activity
BE2017 / 5621 immunostimulatory potential vaccine.
useful in vivo. appropriate in
They are as well as adjutants
BE2017 / 5621

权利要求:
Claims (39)
[1]
1. Compound of formula (I):
in which :
Ri represents -O-Z- (P (= 0) -OH) -O-Y-A
R2 represents H, C1 to CV alkyl, C1 to CR-amino alkyl, C1 to CV alkoxy, C3 to C6 cycloalkyl-C1 to CV alkyl, C3 to CR cycloalkyl-C1 to C6 alkyl -amino, C3-CR cycloalkyl-C1-CV alkoxy, C1-CR alkoxy-C1-CV alkyl, C1-C1 alkoxy-CR
C1-C6-amino, C1-C6 alkoxy-C1-C6 alkoxy; and optionally substituted at the end with a hydroxyl, amino, -NHNH2, N3, -C ^ CH, -COOH, or maleimido group;
Z represents a group (C2 to C6-0 alkylene) _q ;
Y represents a group (C2 to C6-0 alkylene) _r ;
20 q represents an integer 1 to 6;
r represents 0 or an integer 1 to 20;
R3 represents a C2 to CR-OH alkylene, C2 to C6-NH2 alkylene, C2 to C5-CH2-OH alkenyl or C2 to C5-CH2-NH2 alkenyl group;
BE2017 / 5621
Hâëï ^ / '• S ,. „Z <XA represents in which:
R4 represents H, C4 to C24 alkyl, C4 to C24 alkenyl, —CO-C3 to C23 alkyl, or —CO C3 to C23 alkenyl;
R5 represents C4 to C24 alkyl, C4 to C24 alkenyl, —CO-C3 to C23 alkyl, or — C3 to C23 alkenyl;
p represents 0 or an integer 1 to 6; or one of their pharmaceutically acceptable salts.
[2]
2. A compound according to claim 1, wherein R2 represents H, a C1-C6 alkyl or C1-C6 alkoxy-C1-C6 alkyl.
[3]
3. A compound according to claim 1 or claim 2, wherein r represents 0 or an integer 1 to 3.
[4]
4. A compound according to any one of claims 1 to 3, in which R3 represents a C2 to Cb-OH alkylene group.
[5]
5. Compound according to any one of claims 1 to 4, in which p represents an integer 1 to 3.
[6]
6. Compound according to any one of claims 1 to 5, in which A represents
i ........ i -
BE2017 / 5621
[7]
7. Compound according to claim 1, which is a compound of formula (IA):
in which :
R1 represents -O-Z-O- (P (= 0) -OH) -O-Y-A R2 represents H, C1-C6 alkyl or C1-C3 alkoxy-C1-C3 alkyl;
Z represents a group (C2 to C6-0 alkylene) _q ;
Y represents a group (C2 to C6-0 alkylene) _r ;
q represents an integer 1 to 6;
r represents 0 or an integer 1 to 20;
R3 represents a C2 to C6-OH alkylene group;
A represents ’* in which:
R4 represents H, a group —CO-C3 to C23 alkyl, or —CO-C3 to C23 alkenyl;
R5 represents a group —CO-C3 to C23 alkyl, or - C3 to C23 alkenyl;
or one of its pharmaceutically acceptable salts.
[8]
8. Compound according to any one of claims 1 to 7, in which R2 represents H, an n-butyl group or CH3CH2OCH2-.
BE2017 / 5621
[9]
9. A compound according to claim 8, wherein R2 represents an n-butyl group.
[10]
10. Compound according to any one of claims 1 to 9, in which Z represents CH2CH2O.
[11]
11. Compound according to claims 1 to 10, ((CH ₂ ) 2O) _r .
[12]
12. Compound according to any one of, in which Y represents any one of claims 1 to 11, in which q represents an integer 1 to 3, particularly 1 or 3 and especially 1.
[13]
13. Compound according to any one of claims 1 to 12, in which r represents 0 or an integer 1 to 6.
[14]
14. A compound according to claim 13, in which r represents 0.
[15]
15. Compound claims 1
CH2CH2OH.
[16]
16. A compound according to any one of 14, in which R3 represents any of claims 1 to 15, in which R4 represents H and R5 represents a group —CO-C3 to C23 alkyl, or —CO C3 alkenyl to C23.
[17]
17. A compound according to any one of claims 1 to 15, in which R4 and R5 independently represent a —CO-C3 to C23 alkyl or - COalkenyl to C3 to C23 group.
[18]
18. Compound according to any one of claims 1 to 15, in which R4 and R5 independently represent a lauroyl, myristoyl, palmitoyl, oleoyl or linoleoyl group, preferably oleoyl or palmitoyl, especially oleoyl.
BE2017 / 5621
[19]
19. A compound according to any one of claims 1 to 15, 17 or 18, in which R4 and R5 are identical.
[20]
20. Compound according to claim 1 chosen from examples 1 to 7 and their pharmaceutically acceptable salts.
[21]
21. Compound according to claim 20 chosen from Example 1 and its pharmaceutically acceptable salts.
[22]
22. Pharmaceutical composition or vaccine composition or immunogenic composition comprising a compound according to any one of claims 1 to 21
[23]
23. The pharmaceutical composition according to claim 22 which comprises a vaccine antigen.
[24]
24. The composition of claim 23, wherein the antigen is a cancerous antigen.
[25]
25. The composition of claim 23, wherein the antigen is an antigen derived from a pathogen.
[26]
26. A method of inducing an immune response in a mammal which comprises administering to said mammal in need of an immunostimulatory amount of a compound or composition according to any one of claims 1 to 25.
[27]
27. A compound of the invention or composition according to any of claims 1 to 25 for use in the induction of an immune response in a mammal.
[28]
28. A method of inducing protective immunity against a disease in a mammal which comprises administering to a mammal in need of an immunostimulatory amount of a compound according to one
BE2017 / 5621 any one of claims 1 to 21 in conjunction with a pathological antigen.
[29]
29. A method of treatment or prophylaxis of cancer in a mammal which comprises administering to a mammal in need of an immunostimulatory amount of a compound according to any one of claims 1 to 21 together with a cancer antigen.
[30]
30. Compound of formula (II):
in which :
Ria represents -O-Z-H;
and Z, R2 and R3 are defined according to any one of claims 1 to 21;
or one of its protected derivatives.
[31]
31. Compound of formula (VI) in which:
BE2017 / 5621
Ria represents -O-Z-H;
and Z, R2 and R3 are defined according to any one of claims 1 to 21;
or one of its protected derivatives.
[32]
32. A compound according to any one of claims 1 to 21, 27, 30 or 31, which is a choline salt.
[33]
33. A compound according to claim 32, wherein the choline salt is chosen from choline bicarbonate and choline hydroxide.
[34]
34. Process for the preparation of a choline salt of a compound according to any one of claims 1 to 21, 27, 30 or 31, comprising:
(at) the dissolution of the compound in a vehicle aqueous; (b) the addition of choline salt ; and (vs) the mixture of compound and salt choline; in which the process does not include
the use of an organic solvent.
[35]
35. The method of claim 34, wherein the aqueous vehicle is glycerol in water.
[36]
36. The method of claim 34, wherein the choline salt is selected from choline bicarbonate and choline hydroxide.
[37]
37. Process for the preparation of a choline salt of a compound according to any one of claims 1 to 21, 27, 30 or 31, comprising:
(a) dissolving the compound in an organic solvent;
(b) adding the choline salt;
(c) mixing the compound and the choline salt; and
BE2017 / 5621 (d) elimination of the organic solvent; wherein the method does not include a vacuum drying step.
[38]
38. The method of claim 37, wherein the organic solvent is THF.
[39]
39. The method of claim 37, wherein the choline salt is selected from choline bicarbonate and choline hydroxide.
BE2017 / 5621
NFkB activity report (SEAP) / NFkB activity report (SEAP) /
Vehicle light Vehicle light
Concentration (M)

类似技术:

---

公开号 | 公开日 | 专利标题

---

BE1024865B1|2018-07-31|IMIDAZOQUINOLEINE DERIVATIVES

---

BE1024097B1|2017-11-16|IMIDAZOQUINOLINE PEGYLENE

---

RU2664534C2|2018-08-20|Tenofovir prodrug and pharmaceutical uses thereof

---

EP3390416B1|2020-08-19|Phospholipidation of imidazoquinolines and oxoadenines

---

CA2337807C|2012-08-21|Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same

---

WO2014026582A1|2014-02-20|Tenofovir diester compound, preparation method and use thereof, and pharmaceutical composition comprising the same

---

EP1242365A1|2002-09-25|Acyl pseudodipeptides which carry a functionalised auxiliary arm

---

CA2436958A1|2002-08-08|Pyrimidine acyclonucleoside derivatives, preparation method and use thereof

---

EP0448550A1|1991-10-02|New derivatives of deoxy-2&#39;-uridine substituted in the 5, 3&#39; or 5&#39; position by acylated alpha-amino groups, process for obtaining them and drugs containing them.

---

US11274115B2|2022-03-15|Imidazoquinoline derivatives and their use in therapy

---

JP2012520857A|2012-09-10|Aminocyclitol compounds, methods for obtaining them and uses thereof

---

RU2647576C1|2018-03-16|Cyclobutyl |-2-[[[r)-2-|-1-methyl-etoxy]methyl-phenoxy-phosphoryl]amino]-propanoates, method of their production and application

---

EP2691402B1|2019-05-08|Bifunctional hydroxy-bisphosphonic acid derivatives

---

KR900006132B1|1990-08-24|Gem - dihalo - 1,8 -diamino - 4- aza - octane

---

EP3925963A1|2021-12-22|Phytosphingosine derivatives as adjuvants in immune stimulation

---

WO2021261444A1|2021-12-30|Adjuvant with tlr4 agonist activity

---

JP6359409B2|2018-07-18|Funiculosin derivative having toll-like receptor 4 activation action and use thereof

---

JP2021525773A|2021-09-27|TLR7 peptide conjugate

同族专利:

---

公开号 | 公开日

---

WO2018046460A1|2018-03-15|

---

ES2893166T3|2022-02-08|

---

EP3510036B1|2021-07-21|

---

US20210277038A1|2021-09-09|

---

EP3510036A1|2019-07-17|

---

BE1024865A1|2018-07-24|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

WO2005020999A1|2003-08-27|2005-03-10|3M Innovative Properties Company|Aryloxy and arylalkyleneoxy substituted imidazoquinolines|

---

WO2007100634A2|2006-02-22|2007-09-07|3M Innovative Properties Company|Immune response modifier conjugates|

---

WO2010048520A1|2008-10-24|2010-04-29|Glaxosmithkline Biologicals Sa|Lipidated imidazoquinoline derivatives|

---

WO2012031140A1|2010-09-01|2012-03-08|Novartis Ag|Adsorption of immunopotentiators to insoluble metal salts|

---

WO2017102652A1|2015-12-14|2017-06-22|Glaxosmithkline Biologicals S.A.|Pegylated imidazoquinolines as tlr7 and tlr8 agonists|

---

WO2017102654A1|2015-12-14|2017-06-22|Glaxosmithkline Biologicals S.A.|Phospholipidation of imidazoquinolines and oxoadenines|

---

KR20190026761A|2016-07-07|2019-03-13|더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티|Antibody-adjuvant conjugate|

---

SG10201914029RA|2016-10-14|2020-03-30|Precision Biosciences Inc|Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome|

---

US10966999B2|2017-12-20|2021-04-06|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein|

---

US11203610B2|2017-12-20|2021-12-21|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein|

---

KR20200124716A|2018-02-26|2020-11-03|길리애드 사이언시즈, 인코포레이티드|Substituted pyrrolysine compounds as inhibitors of HBV replication|

---

EP3774883A1|2018-04-05|2021-02-17|Gilead Sciences, Inc.|Antibodies and fragments thereof that bind hepatitis b virus protein x|

---

TW202005655A|2018-04-06|2020-02-01|捷克科學院有機化學與生物化學研究所|2'3'-cyclic dinucleotides|

---

TW202010503A|2018-04-06|2020-03-16|捷克科學院有機化學與生物化學研究所|3’3’－cyclic dinucleotides|

---

TW202005654A|2018-04-06|2020-02-01|捷克科學院有機化學與生物化學研究所|2'2'-cyclic dinucleotides|

---

TW201945388A|2018-04-12|2019-12-01|美商精密生物科學公司|Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis B virus genome|

---

TW202014193A|2018-05-03|2020-04-16|捷克科學院有機化學與生物化學研究所|2’3’-cyclic dinucleotides comprising carbocyclic nucleotide|

---

WO2020028097A1|2018-08-01|2020-02-06|Gilead Sciences, Inc.|Solid forms of -11--12--3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid|

---

EP3873608A1|2018-10-31|2021-09-08|Gilead Sciences, Inc.|Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity|

---

CR20210215A|2018-10-31|2021-06-17|Gilead Sciences Inc|Substituted 6-azabenzimidazole compounds as hpk1 inhibitors|

---

WO2020178768A1|2019-03-07|2020-09-10|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator|

---

WO2020178770A1|2019-03-07|2020-09-10|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|3'3'-cyclic dinucleotides and prodrugs thereof|

---

WO2020178769A1|2019-03-07|2020-09-10|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|2'3'-cyclic dinucleotides and prodrugs thereof|

---

WO2020190762A1|2019-03-15|2020-09-24|Bolt Biotherapeutics, Inc.|Macromolecule-supported tlr agonists|

---

EP3949983A1|2019-04-05|2022-02-09|Sumitomo Dainippon Pharma Co., Ltd.|Water soluble adjuvant|

---

WO2020214663A1|2019-04-17|2020-10-22|Gilead Sciences, Inc.|Solid forms of a toll-like receptor modulator|

---

EP3956329A1|2019-04-17|2022-02-23|Gilead Sciences, Inc.|Solid forms of a toll-like receptor modulator|

---

WO2020237025A1|2019-05-23|2020-11-26|Gilead Sciences, Inc.|Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors|

---

WO2021034804A1|2019-08-19|2021-02-25|Gilead Sciences, Inc.|Pharmaceutical formulations of tenofovir alafenamide|

---

WO2021067181A1|2019-09-30|2021-04-08|Gilead Sciences, Inc.|Hbv vaccines and methods treating hbv|

---

WO2021113765A1|2019-12-06|2021-06-10|Precision Biosciences, Inc.|Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome|

---

WO2021188959A1|2020-03-20|2021-09-23|Gilead Sciences, Inc.|Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same|

法律状态:
2018-10-03| FG| Patent granted|Effective date: 20180731 |

---

2020-08-06| MM| Lapsed because of non-payment of the annual fee|Effective date: 20190930 |

优先权:

---

申请号 | 申请日 | 专利标题

---

US201662384618P| true| 2016-09-07|2016-09-07|

---

US62384618|2016-09-07|

---